| |

Injectable Pemetrexed for Mesothelioma Now Available for the First Time

ByAlex Strauss
injectable pemetrexed for mesothelioma

The FDA has cleared injectable pemetrexed for mesothelioma after two drug companies settled a patent dispute over the medication in December.

Until now, the chemotherapy drug pemetrexed has only been available for infusion. In this form, it is called Alimta and is distributed by Eli Lilly. 

But New Jersey-based Eagle Pharmaceuticals wanted to develop a form of injectable pemetrexed for mesothelioma. They received tentative approval for the drug in 2018, but it was not until the patent issue was settled that the final approval was granted. 

The drug may shorten the duration of treatment for some patients with malignant mesothelioma. 

Pemetrexed the Primary Mesothelioma Treatment

Malignant mesothelioma is an intractable cancer that grows on the membranes around internal organs. Patients diagnosed with this devastating disease do not usually live more than about a year after diagnosis. 

Until last year, Alimta was the only FDA-approved treatment for malignant mesothelioma. Last year, an electrically-based external treatment called Tumor Treating Fields also won FDA approval for mesothelioma. Alimta was still the only approved drug. 

In 2017, Eagle Pharmaceuticals tried to introduce injectable pemetrexed for mesothelioma. Eli Lilly argued that they held the patent for pemetrexed. This kept the injectable form, called Pemfexy, out of the US market. 

On December 31, the two companies reached a settlement. This allowed the FDA to shift approval of injectable pemetrexed for mesothelioma from tentative to final. A limited supply of the drug was released on February 1. The full supply will be available April 1.

“We are pleased to receive final approval from FDA and look forward to making Pemfexy available to the patients who can benefit,” Eagle CEO Scott Tarriff said in a news release. “Our initial market exclusivity for Pemfexy represents a significant opportunity for Eagle and builds on the successes of our expanding presence in the oncology space.” 

The Evolution of Pemetrexed

The development of injectable pemetrexed for mesothelioma has been an evolution.

The FDA approved Alimta as the first mesothelioma treatment in 2004. It’s approval was fast-tracked under the “compassionate use” provision because there were so few options for mesothelioma patients. Alimta’s developer was a chemistry professor from Princeton University. Dr. Edward Taylor worked on the formulation of pemetrexed for decades. 

Today, Alimta, in combination with cisplatin, is the first-line mesothelioma treatment for most patients. It is also approved for non-small cell lung cancer treatment. 

Injectable pemetrexed for mesothelioma is just the latest iteration of this life-saving drug. It is approved for mesothelioma patients who are not candidates for surgery, for whatever reason. It is also approved for certain patients with non-small cell lung cancer.

Pemetrexed is likely to continue to evolve. A group of scientists in India and Saudi Arabia are experimenting with an oral form of the drug. 

Sources:

Eagle Pharmaceuticals receives final FDA approval for Pemfexy (pemetrexed for injection), February 10, 2020, News Release, Eagle Pharmaceuticals, https://bit.ly/2SircfX

Soni, K, et al, “Development of pemetrexed diacid-loaded Gelatin-Cloisite 30B (MMT) nanocomposite for improved oral efficacy against cancer: Characterization, In-vitro and Ex-vivo Assessment”, February 10, 2020, Current Drug Delivery, Epub ahead of print, http://www.eurekaselect.com/179185/article

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…